Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 05, 2018

Measurable Residual Disease at Induction Redefines Partial Response in AML

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
J. Clin. Oncol 2018 Mar 30;[EPub Ahead of Print], SD Freeman, RK Hills, P Virgo, N Khan, S Couzens, R Dillon, A Gilkes, L Upton, OJ Nielsen, JD Cavenagh, G Jones, A Khwaja, P Cahalin, I Thomas, D Grimwade, AK Burnett, NH Russell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading